Overview

* Dogwood Q3 net loss widens to $15.7 mln, driven by increased R&D expenses

* Research and development expenses rose significantly due to SP16 licensing costs

* Company secured exclusive license for SP16 in an all-stock transaction

Outlook

* Final data for Halneuron expected in the second half of 2026

* SP16 Phase 1b study to commence after FDA consultation

Result Drivers

* Research and development expenses for the third quarter of 2025 were $14.5 million, compared to $0.5 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$8.20

Q3 Net -$15.70

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Dogwood Therapeutics Inc ( DWTX ) is $13.00, about 57.2% above its November 5 closing price of $5.56

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)